567616

Sodium 4-Phenylbutyrate

A novel anti-neoplastic agent and transcriptional regulator.

• Sinónimos: Sodium 4-Phenylbutyrate, SPB, PBNa, 4PBA, 4-Phenylbutyrate, Na, BCKD Kinase Inhibitor I, Branched-Chain α-Ketoacid Dehydrogenase Kinase Inhibitor I, BDK Inhibitor I
• Fórmula empírica (notación de Hill): C₁₀H₁₁NaO₂
• Número de CAS: 1716-12-7
• Peso molecular: 186.18
• Número MDL: MFCD00800247
• Código UNSPSC: 12352200

Propiedades

• Nivel de calidad: 100
• Análisis: ≥98% (HPLC)
• formulario: solid
• fabricante / nombre comercial: Calbiochem^®
• condiciones de almacenamiento: OK to freeze; desiccated (hygroscopic)
• color: white to slightly yellow
• solubilidad: water: 10 mg/mL
• Condiciones de envío: ambient
• temp. de almacenamiento: −20°C
• InChI: 1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
• Clave InChI: VPZRWNZGLKXFOE-UHFFFAOYSA-M

Descripción

Descripción general

A novel anti-neoplastic agent and transcriptional regulator. Also acts as an inducer of tumor cytostasis and differentiation. Increases fetal hemoglobin production in vitro and in vivo.

An antineoplastic agent that demonstrates potent differentiating capacity in multiple hematopoietic and solid tumor cell lines. Acts as an inducer of tumor cytostasis and differentiation as well as of peroxisomal proliferation. A more effective inhibitor of histone deacetylase and inducer of histone acetylation than its structural analogs including 2- and 3-phenylbutyrate. Acts as a transcriptional regulator and improve the targeting of δF508-CFTR (cystic fibrosis transmembrane regulator) for ubiquitination and degradation by reducing the expression of HSC70 in epithelial cells. Also, reported to increase fetal hemoglobin production in vitro and in vivo.

Acciones bioquímicas o fisiológicas

Cell permeable: no

Primary Target
Anti-neoplastic agent

Product does not compete with ATP.

Reversible: no

Advertencia

Toxicity: Standard Handling (A)

Reconstitución

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Otras notas

Tso, S.C., et al. 2013. Proc. Natl. Acad. Sci. USA110, 9728.
Ozcan, U., et al. 2006. Science313, 1137.
Carducci, M.A., et al. 2001. Clin. Cancer Res.7, 3047.
Rubenstein, R.C. and Zeitlin, P.L. 2000. Am.J. Physiol. Cell. Physiol.278, C259.
Lea, M.A., et al. 1999. Anticancer Res.19, 1971.
Miller, A.C., et al. 1997. Int. J. Radiat. Biol. 72, 211.
Rubenstein, R.C., et al. 1997. J. Clin. Invest. 100, 2457.
Pineau, T., et al. 1996. Biochem. Pharmacol. 52, 659.
Collins, A.F., et al. 1995. Blood 85, 43.
Lea, M.A., et al. 1995. Anticancer Res.15, 879.
Figg, W.D., et al. 1994. Anticancer Drugs 5, 336.
Liu, L., et al. 1994. J. Invest. Dermatol. 103, 335.

Información legal

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Código de clase de almacenamiento: 11 - Combustible Solids
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable